{"id":483,"date":"2026-04-08T14:31:03","date_gmt":"2026-04-08T07:31:03","guid":{"rendered":"https:\/\/cctravelesthetic.com\/?p=483"},"modified":"2026-04-08T14:31:10","modified_gmt":"2026-04-08T07:31:10","slug":"leonatide-dieu-tri-dai-thao-duong-voi-tirzepatide","status":"publish","type":"post","link":"https:\/\/cctravelesthetic.com\/vi\/leonatide-dieu-tri-dai-thao-duong-voi-tirzepatide\/","title":{"rendered":"LEONATIDE \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng v\u1edbi (TIRZEPATIDE)"},"content":{"rendered":"\n\n\n
\n

Th\u00f4ng \u0111i\u1ec7p ch\u00ednh:\u00a0<\/strong>Tirzepatide l\u00e0 thu\u1ed1c \u0111\u1ed3ng v\u1eadn k\u00e9p GIP\/GLP-1, ti\u00eam d\u01b0\u1edbi da 1 l\u1ea7n\/tu\u1ea7n, c\u00f3 hi\u1ec7u qu\u1ea3 h\u1ea1 HbA1c v\u00e0 gi\u1ea3m c\u00e2n r\u1ea5t m\u1ea1nh. Thu\u1ed1c \u0111\u1eb7c bi\u1ec7t h\u1eefu \u00edch \u1edf ng\u01b0\u1eddi \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 c\u00f3 th\u1eeba c\u00e2n\/b\u00e9o ph\u00ec, nh\u01b0ng c\u1ea7n ch\u1ecdn \u0111\u00fang b\u1ec7nh nh\u00e2n, t\u0103ng li\u1ec1u t\u1eeb t\u1eeb v\u00e0 theo d\u00f5i t\u00e1c d\u1ee5ng ph\u1ee5 ti\u00eau h\u00f3a, nguy c\u01a1 m\u1ea5t n\u01b0\u1edbc, vi\u00eam t\u1ee5y, b\u1ec7nh t\u00fai m\u1eadt v\u00e0 c\u00e1c c\u1ea3nh b\u00e1o \u0111\u1eb7c hi\u1ec7u.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

M\u1ee4C L\u1ee4C N\u1ed8I DUNG<\/strong><\/h1>\n

1. Tirzepatide l\u00e0 g\u00ec?<\/p>\n

2. C\u00f4ng d\u1ee5ng v\u00e0 c\u01a1 ch\u1ebf \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng<\/p>\n

3. \u01afu v\u00e0 nh\u01b0\u1ee3c \u0111i\u1ec3m so v\u1edbi c\u00e1c nh\u00f3m thu\u1ed1c \u0111i\u1ec1u tr\u1ecb kh\u00e1c<\/p>\n

4. Ch\u1ec9 \u0111\u1ecbnh v\u00e0 ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh<\/p>\n

5. T\u00e1c d\u1ee5ng ph\u1ee5 v\u00e0 c\u1ea3nh b\u00e1o an to\u00e0n<\/p>\n

6. Li\u1ec1u d\u00f9ng v\u00e0 c\u00e1ch d\u00f9ng<\/p>\n

7. T\u00ednh h\u1ee3p ph\u00e1p t\u1ea1i Vi\u1ec7t Nam v\u00e0 tr\u00ean th\u1ebf gi\u1edbi<\/p>\n

8. C\u00e1c nghi\u00ean c\u1ee9u l\u1edbn v\u1ec1 tirzepatide trong \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng<\/p>\n

9. K\u1ebft lu\u1eadn th\u1ef1c h\u00e0nh v\u00e0 t\u00e0i li\u1ec7u tham kh\u1ea3o<\/p>\n

1. Tirzepatide l\u00e0 g\u00ec?<\/strong><\/h1>\n

Tirzepatide l\u00e0 m\u1ed9t thu\u1ed1c \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 d\u00f9ng \u0111\u01b0\u1eddng ti\u00eam d\u01b0\u1edbi da, 1 l\u1ea7n m\u1ed7i tu\u1ea7n. \u0110\u00e2y l\u00e0 thu\u1ed1c \u201c\u0111\u1ed3ng v\u1eadn k\u00e9p\u201d tr\u00ean hai th\u1ee5 th\u1ec3 incretin: GIP (glucose-dependent insulinotropic polypeptide) v\u00e0 GLP-1 (glucagon-like peptide-1). V\u1ec1 m\u1eb7t d\u01b0\u1ee3c l\u00fd, \u0111\u00e2y kh\u00f4ng ch\u1ec9 l\u00e0 m\u1ed9t GLP-1 receptor agonist th\u00f4ng th\u01b0\u1eddng, m\u00e0 l\u00e0 m\u1ed9t GIP\/GLP-1 receptor agonist \u0111\u1ea7u ti\u00ean \u0111\u01b0\u1ee3c \u0111\u01b0a v\u00e0o th\u1ef1c h\u00e0nh l\u00e2m s\u00e0ng.<\/p>\n

Trong c\u00e1c t\u00e0i li\u1ec7u c\u1ee7a ADA, tirzepatide \u0111\u01b0\u1ee3c x\u1ebfp v\u00e0o nh\u00f3m thu\u1ed1c c\u00f3 hi\u1ec7u qu\u1ea3 r\u1ea5t cao \u0111\u1ed1i v\u1edbi c\u1ea3 h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft l\u1eabn gi\u1ea3m c\u00e2n. EMA m\u00f4 t\u1ea3 Mounjaro (ho\u1ea1t ch\u1ea5t tirzepatide) l\u00e0 thu\u1ed1c d\u00f9ng c\u00f9ng ch\u1ebf \u0111\u1ed9 \u0103n v\u00e0 ho\u1ea1t \u0111\u1ed9ng th\u1ec3 l\u1ef1c \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 ki\u1ec3m so\u00e1t ch\u01b0a \u0111\u1ea1t, c\u00f3 th\u1ec3 d\u00f9ng \u0111\u01a1n tr\u1ecb khi metformin kh\u00f4ng ph\u00f9 h\u1ee3p ho\u1eb7c d\u00f9ng ph\u1ed1i h\u1ee3p v\u1edbi c\u00e1c thu\u1ed1c kh\u00e1c.<\/p>\n

\u2022 T\u00ean ho\u1ea1t ch\u1ea5t: tirzepatide.<\/p>\n

\u2022 T\u00ean bi\u1ec7t d\u01b0\u1ee3c qu\u1ed1c t\u1ebf ph\u1ed5 bi\u1ebfn: Mounjaro (\u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2); \u1edf m\u1ed9t s\u1ed1 th\u1ecb tr\u01b0\u1eddng c\u00f3 t\u00ean kh\u00e1c khi \u0111\u0103ng k\u00fd cho ki\u1ec3m so\u00e1t c\u00e2n n\u1eb7ng.<\/p>\n

\u2022 D\u1ea1ng d\u00f9ng: dung d\u1ecbch ti\u00eam d\u01b0\u1edbi da, d\u00f9ng 1 l\u1ea7n\/tu\u1ea7n.<\/p>\n

\u2022 Kh\u00f4ng ph\u1ea3i insulin, kh\u00f4ng d\u00f9ng \u0111\u1ec3 thay th\u1ebf insulin trong \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 1 ho\u1eb7c nhi\u1ec5m toan ceton do \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng.<\/p>\n

\n\n\n\n
\n

Gi\u1ea3i th\u00edch cho ng\u01b0\u1eddi b\u1ec7nh:\u00a0<\/strong>tirzepatide l\u00e0 thu\u1ed1c ti\u00eam m\u1ed7i tu\u1ea7n 1 l\u1ea7n gi\u00fap c\u01a1 th\u1ec3 ti\u1ebft insulin \u201c\u0111\u00fang l\u00fac h\u01a1n\u201d, gi\u1ea3m \u0111\u01b0\u1eddng huy\u1ebft sau \u0103n, gi\u1ea3m c\u1ea3m gi\u00e1c \u0111\u00f3i v\u00e0 h\u1ed7 tr\u1ee3 gi\u1ea3m c\u00e2n. Thu\u1ed1c kh\u00f4ng c\u00f3 ngh\u0129a l\u00e0 thay th\u1ebf ho\u00e0n to\u00e0n \u0103n u\u1ed1ng, v\u1eadn \u0111\u1ed9ng v\u00e0 theo d\u00f5i \u0111\u01b0\u1eddng huy\u1ebft.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

2. C\u00f4ng d\u1ee5ng v\u00e0 c\u01a1 ch\u1ebf \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng<\/strong><\/h1>\n

Tirzepatide c\u00f3 hai gi\u00e1 tr\u1ecb n\u1ed5i b\u1eadt trong \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2: (1) h\u1ea1 HbA1c m\u1ea1nh, v\u00e0 (2) gi\u1ea3m c\u00e2n \u0111\u00e1ng k\u1ec3. Trong nghi\u00ean c\u1ee9u SURPASS, m\u1ee9c gi\u1ea3m HbA1c \u1edf c\u00e1c th\u1eed nghi\u1ec7m pha 3 ho\u00e0n t\u1ea5t dao \u0111\u1ed9ng kho\u1ea3ng 1,87% \u0111\u1ebfn 2,59%, \u0111\u1ed3ng th\u1eddi gi\u1ea3m c\u00e2n kho\u1ea3ng 6,2 kg \u0111\u1ebfn 12,9 kg t\u1ea1i c\u00e1c m\u1ed1c ch\u00ednh 40\u201352 tu\u1ea7n.<\/p>\n

C\u01a1 ch\u1ebf t\u00e1c d\u1ee5ng c\u1ee7a thu\u1ed1c li\u00ean quan \u0111\u1ebfn vi\u1ec7c ho\u1ea1t h\u00f3a \u0111\u1ed3ng th\u1eddi th\u1ee5 th\u1ec3 GIP v\u00e0 GLP-1. \u0110i\u1ec1u n\u00e0y l\u00e0m t\u0103ng ti\u1ebft insulin ph\u1ee5 thu\u1ed9c glucose, gi\u1ea3m ti\u1ebft glucagon khi \u0111\u01b0\u1eddng huy\u1ebft t\u0103ng, l\u00e0m ch\u1eadm r\u1ed7ng d\u1ea1 d\u00e0y v\u00e0 gi\u1ea3m h\u1ea5p thu glucose sau \u0103n, \u0111\u1ed3ng th\u1eddi t\u00e1c \u0111\u1ed9ng l\u00ean trung \u01b0\u01a1ng gi\u00fap gi\u1ea3m c\u1ea3m gi\u00e1c \u0111\u00f3i v\u00e0 l\u01b0\u1ee3ng th\u1ee9c \u0103n n\u1ea1p v\u00e0o.<\/p>\n

M\u1ed9t \u0111i\u1ec3m th\u1ef1c h\u00e0nh quan tr\u1ecdng l\u00e0 tirzepatide hi\u1ebfm khi g\u00e2y h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft khi d\u00f9ng \u0111\u01a1n \u0111\u1ed9c ho\u1eb7c c\u00f9ng metformin\/SGLT2i, nh\u01b0ng nguy c\u01a1 s\u1ebd t\u0103ng r\u00f5 khi ph\u1ed1i h\u1ee3p v\u1edbi sulfonylurea ho\u1eb7c insulin. V\u00ec v\u1eady, khi th\u00eam tirzepatide v\u00e0o ph\u00e1c \u0111\u1ed3 \u0111\u00e3 c\u00f3 insulin n\u1ec1n ho\u1eb7c sulfonylurea, c\u1ea7n c\u00e2n nh\u1eafc gi\u1ea3m li\u1ec1u thu\u1ed1c kia.<\/p>\n

C\u00e1c t\u00e1c \u0111\u1ed9ng sinh l\u00fd ch\u00ednh c\u1ee7a tirzepatide:<\/strong><\/h2>\n
\n\n\n\n\n\n\n\n\n
\n

\u0110\u00edch t\u00e1c \u0111\u1ed9ng<\/strong><\/p>\n<\/td>\n

\n

Hi\u1ec7u \u1ee9ng ch\u00ednh<\/strong><\/p>\n<\/td>\n

\n

\u00dd ngh\u0129a l\u00e2m s\u00e0ng<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

T\u1ebf b\u00e0o beta t\u1ee5y<\/p>\n<\/td>\n

\n

T\u0103ng ti\u1ebft insulin ph\u1ee5 thu\u1ed9c glucose<\/p>\n<\/td>\n

\n

H\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft m\u1ea1nh nh\u01b0ng \u00edt h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft khi kh\u00f4ng ph\u1ed1i h\u1ee3p insulin\/SU<\/p>\n<\/td>\n<\/tr>\n

\n

T\u1ebf b\u00e0o alpha t\u1ee5y<\/p>\n<\/td>\n

\n

Gi\u1ea3m glucagon khi \u0111\u01b0\u1eddng huy\u1ebft t\u0103ng<\/p>\n<\/td>\n

\n

Gi\u1ea3m s\u1ea3n xu\u1ea5t glucose \u1edf gan, h\u1ed7 tr\u1ee3 ki\u1ec3m so\u00e1t \u0111\u01b0\u1eddng huy\u1ebft l\u00fac \u0111\u00f3i v\u00e0 sau \u0103n<\/p>\n<\/td>\n<\/tr>\n

\n

D\u1ea1 d\u00e0y-ru\u1ed9t<\/p>\n<\/td>\n

\n

L\u00e0m ch\u1eadm r\u1ed7ng d\u1ea1 d\u00e0y<\/p>\n<\/td>\n

\n

Gi\u1ea3m t\u0103ng \u0111\u01b0\u1eddng huy\u1ebft sau \u0103n; \u0111\u1ed3ng th\u1eddi g\u00e2y bu\u1ed3n n\u00f4n\/n\u00f4n \u1edf giai \u0111o\u1ea1n \u0111\u1ea7u<\/p>\n<\/td>\n<\/tr>\n

\n

N\u00e3o\/trung t\u00e2m \u0103n u\u1ed1ng<\/p>\n<\/td>\n

\n

Gi\u1ea3m c\u1ea3m gi\u00e1c \u0111\u00f3i, t\u0103ng c\u1ea3m gi\u00e1c no<\/p>\n<\/td>\n

\n

Gi\u1ea3m c\u00e2n, c\u1ea3i thi\u1ec7n kh\u00e1ng insulin gi\u00e1n ti\u1ebfp<\/p>\n<\/td>\n<\/tr>\n

\n

Chuy\u1ec3n h\u00f3a to\u00e0n th\u00e2n<\/p>\n<\/td>\n

\n

C\u1ea3i thi\u1ec7n c\u00e2n n\u1eb7ng, huy\u1ebft \u00e1p, lipid v\u00e0 m\u1ed9t s\u1ed1 ch\u1ec9 d\u1ea5u chuy\u1ec3n h\u00f3a<\/p>\n<\/td>\n

\n

H\u1eefu \u00edch \u1edf ng\u01b0\u1eddi b\u1ec7nh t\u00edp 2 c\u00f3 b\u00e9o ph\u00ec, b\u1ec7nh l\u00fd tim-th\u1eadn-chuy\u1ec3n h\u00f3a \u0111i k\u00e8m<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

3. \u01afu v\u00e0 nh\u01b0\u1ee3c \u0111i\u1ec3m so v\u1edbi c\u00e1c nh\u00f3m thu\u1ed1c \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng kh\u00e1c<\/strong><\/h1>\n

Trong l\u1ef1a ch\u1ecdn thu\u1ed1c h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft hi\u1ec7n nay, kh\u00f4ng c\u00f3 m\u1ed9t thu\u1ed1c n\u00e0o \u201ct\u1ed1t nh\u1ea5t cho m\u1ecdi b\u1ec7nh nh\u00e2n\u201d. Tirzepatide n\u1ed5i b\u1eadt v\u1ec1 hi\u1ec7u qu\u1ea3 h\u1ea1 HbA1c v\u00e0 gi\u1ea3m c\u00e2n, nh\u01b0ng gi\u00e1 th\u00e0nh, \u0111\u01b0\u1eddng d\u00f9ng ti\u00eam, t\u00e1c d\u1ee5ng ph\u1ee5 ti\u00eau h\u00f3a v\u00e0 m\u1ed9t s\u1ed1 c\u1ea3nh b\u00e1o an to\u00e0n khi\u1ebfn vi\u1ec7c c\u00e1 th\u1ec3 h\u00f3a v\u1eabn l\u00e0 b\u1eaft bu\u1ed9c.<\/p>\n

\n\n\n\n\n\n\n\n\n\n
\n

Nh\u00f3m thu\u1ed1c<\/strong><\/p>\n<\/td>\n

\n

\u0110i\u1ec3m m\u1ea1nh so v\u1edbi tirzepatide<\/strong><\/p>\n<\/td>\n

\n

\u0110i\u1ec3m y\u1ebfu so v\u1edbi tirzepatide<\/strong><\/p>\n<\/td>\n

\n

Khi n\u00e0o n\u00ean \u01b0u ti\u00ean tirzepatide?<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Metformin<\/p>\n<\/td>\n

\n

R\u1ebb, u\u1ed1ng, kinh nghi\u1ec7m d\u00f9ng l\u00e2u d\u00e0i, th\u01b0\u1eddng l\u00e0 n\u1ec1n t\u1ea3ng \u0111\u1ea7u tay<\/p>\n<\/td>\n

\n

Gi\u1ea3m HbA1c v\u00e0 gi\u1ea3m c\u00e2n k\u00e9m h\u01a1n<\/p>\n<\/td>\n

\n

Khi c\u1ea7n h\u1ea1 HbA1c m\u1ea1nh h\u01a1n ho\u1eb7c ng\u01b0\u1eddi b\u1ec7nh th\u1eeba c\u00e2n\/b\u00e9o ph\u00ec, ki\u1ec3m so\u00e1t ch\u01b0a \u0111\u1ea1t v\u1edbi metformin<\/p>\n<\/td>\n<\/tr>\n

\n

SGLT2i<\/p>\n<\/td>\n

\n

L\u1ee3i \u00edch tim-th\u1eadn r\u1ea5t r\u00f5, \u0111\u01b0\u1eddng u\u1ed1ng, gi\u1ea3m nh\u1eadp vi\u1ec7n suy tim<\/p>\n<\/td>\n

\n

H\u1ea1 HbA1c v\u00e0 gi\u1ea3m c\u00e2n th\u01b0\u1eddng th\u1ea5p h\u01a1n tirzepatide<\/p>\n<\/td>\n

\n

Khi \u01b0u ti\u00ean gi\u1ea3m c\u00e2n m\u1ea1nh ho\u1eb7c HbA1c c\u00f2n cao; c\u00f3 th\u1ec3 ph\u1ed1i h\u1ee3p v\u1edbi SGLT2i n\u1ebfu ph\u00f9 h\u1ee3p<\/p>\n<\/td>\n<\/tr>\n

\n

GLP-1 RA \u0111\u01a1n thu\u1ea7n<\/p>\n<\/td>\n

\n

C\u00f9ng h\u01b0\u1edbng incretin, c\u0169ng gi\u00fap gi\u1ea3m c\u00e2n v\u00e0 \u00edt h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft<\/p>\n<\/td>\n

\n

Tirzepatide th\u01b0\u1eddng cho hi\u1ec7u qu\u1ea3 h\u1ea1 HbA1c\/gi\u1ea3m c\u00e2n m\u1ea1nh h\u01a1n trong d\u1eef li\u1ec7u \u0111\u1ea7u \u0111\u1ed1i \u0111\u1ea7u v\u1edbi semaglutide 1 mg<\/p>\n<\/td>\n

\n

Khi mu\u1ed1n t\u1ed1i \u0111a h\u00f3a hi\u1ec7u qu\u1ea3 tr\u00ean \u0111\u01b0\u1eddng huy\u1ebft v\u00e0 c\u00e2n n\u1eb7ng<\/p>\n<\/td>\n<\/tr>\n

\n

DPP-4i<\/p>\n<\/td>\n

\n

U\u1ed1ng, dung n\u1ea1p kh\u00e1 t\u1ed1t, \u00edt t\u00e1c d\u1ee5ng ph\u1ee5 ti\u00eau h\u00f3a<\/p>\n<\/td>\n

\n

Hi\u1ec7u l\u1ef1c h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft y\u1ebfu h\u01a1n r\u00f5, h\u1ea7u nh\u01b0 kh\u00f4ng gi\u1ea3m c\u00e2n<\/p>\n<\/td>\n

\n

Khi c\u1ea7n hi\u1ec7u qu\u1ea3 m\u1ea1nh h\u01a1n v\u00e0 b\u1ec7nh nh\u00e2n ch\u1ea5p nh\u1eadn ti\u00eam<\/p>\n<\/td>\n<\/tr>\n

\n

Sulfonylurea<\/p>\n<\/td>\n

\n

R\u1ebb, h\u1ea1 \u0111\u01b0\u1eddng nhanh<\/p>\n<\/td>\n

\n

G\u00e2y t\u0103ng c\u00e2n v\u00e0 h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft nhi\u1ec1u h\u01a1n<\/p>\n<\/td>\n

\n

Khi c\u1ea7n tr\u00e1nh h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft ho\u1eb7c mu\u1ed1n gi\u1ea3m c\u00e2n<\/p>\n<\/td>\n<\/tr>\n

\n

Insulin n\u1ec1n<\/p>\n<\/td>\n

\n

Hi\u1ec7u l\u1ef1c r\u1ea5t m\u1ea1nh, d\u00f9ng \u0111\u01b0\u1ee3c khi t\u0103ng \u0111\u01b0\u1eddng n\u1eb7ng<\/p>\n<\/td>\n

\n

Ti\u00eam h\u1eb1ng ng\u00e0y, t\u0103ng c\u00e2n, h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft<\/p>\n<\/td>\n

\n

Khi b\u1ec7nh nh\u00e2n t\u00edp 2 c\u00f3 b\u00e9o ph\u00ec v\u00e0 ch\u01b0a b\u1eaft bu\u1ed9c ph\u1ea3i l\u00ean insulin to\u00e0n ph\u1ea7n; tirzepatide c\u0169ng c\u00f3 th\u1ec3 ph\u1ed1i h\u1ee3p insulin n\u1ec1n<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

T\u00f3m t\u1eaft th\u1ef1c h\u00e0nh:<\/strong><\/h2>\n

\u2022 \u01afu \u0111i\u1ec3m l\u1edbn nh\u1ea5t: h\u1ea1 HbA1c r\u1ea5t m\u1ea1nh, gi\u1ea3m c\u00e2n m\u1ea1nh, nguy c\u01a1 h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft th\u1ea5p n\u1ebfu kh\u00f4ng \u0111i k\u00e8m insulin\/SU, ti\u00eam 1 l\u1ea7n\/tu\u1ea7n.<\/p>\n

\u2022 Nh\u01b0\u1ee3c \u0111i\u1ec3m ch\u00ednh: bu\u1ed3n n\u00f4n\/ti\u00eau ch\u1ea3y\/t\u00e1o b\u00f3n, c\u1ea7n t\u0103ng li\u1ec1u ch\u1eadm, l\u00e0 thu\u1ed1c ti\u00eam, gi\u00e1 cao, kh\u00f4ng ph\u00f9 h\u1ee3p cho m\u1ed9t s\u1ed1 nh\u00f3m c\u00f3 ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh\/c\u1ea3nh b\u00e1o \u0111\u1eb7c hi\u1ec7u.<\/p>\n

\u2022 So v\u1edbi SGLT2i: tirzepatide th\u01b0\u1eddng m\u1ea1nh h\u01a1n v\u1ec1 HbA1c v\u00e0 gi\u1ea3m c\u00e2n; SGLT2i v\u1eabn r\u1ea5t quan tr\u1ecdng n\u1ebfu \u01b0u ti\u00ean suy tim ho\u1eb7c b\u1ec7nh th\u1eadn m\u1ea1n.<\/p>\n

\u2022 So v\u1edbi GLP-1 RA: tirzepatide l\u00e0 b\u01b0\u1edbc ti\u1ebfn v\u1ec1 hi\u1ec7u l\u1ef1c, nh\u01b0ng kh\u00f4ng ph\u1ea3i m\u1ecdi b\u1ec7nh nh\u00e2n \u0111\u1ec1u c\u1ea7n m\u1ee9c hi\u1ec7u l\u1ef1c cao nh\u1ea5t n\u1ebfu h\u1ecd kh\u00f4ng dung n\u1ea1p t\u1ed1t ho\u1eb7c kh\u00f4ng \u0111\u1ee7 \u0111i\u1ec1u ki\u1ec7n chi tr\u1ea3.<\/p>\n

4. Ch\u1ec9 \u0111\u1ecbnh v\u00e0 ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh<\/strong><\/h1>\n

Theo FDA, Mounjaro \u0111\u01b0\u1ee3c ch\u1ec9 \u0111\u1ecbnh nh\u01b0 m\u1ed9t thu\u1ed1c b\u1ed5 tr\u1ee3 cho ch\u1ebf \u0111\u1ed9 \u0103n v\u00e0 v\u1eadn \u0111\u1ed9ng nh\u1eb1m c\u1ea3i thi\u1ec7n ki\u1ec3m so\u00e1t \u0111\u01b0\u1eddng huy\u1ebft \u1edf ng\u01b0\u1eddi l\u1edbn m\u1eafc \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2. Theo EMA, ch\u1ec9 \u0111\u1ecbnh r\u1ed9ng h\u01a1n: \u0111i\u1ec1u tr\u1ecb ng\u01b0\u1eddi l\u1edbn, thanh thi\u1ebfu ni\u00ean v\u00e0 tr\u1ebb t\u1eeb 10 tu\u1ed5i tr\u1edf l\u00ean m\u1eafc \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 ki\u1ec3m so\u00e1t ch\u01b0a \u0111\u1ea7y \u0111\u1ee7, d\u00f9ng \u0111\u01a1n tr\u1ecb khi metformin kh\u00f4ng ph\u00f9 h\u1ee3p ho\u1eb7c ph\u1ed1i h\u1ee3p v\u1edbi thu\u1ed1c kh\u00e1c.<\/p>\n

Trong th\u1ef1c h\u00e0nh n\u1ed9i ti\u1ebft, nh\u1eefng nh\u00f3m b\u1ec7nh nh\u00e2n th\u01b0\u1eddng \u0111\u01b0\u1ee3c h\u01b0\u1edfng l\u1ee3i nhi\u1ec1u nh\u1ea5t g\u1ed3m ng\u01b0\u1eddi \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 c\u00f3 th\u1eeba c\u00e2n\/b\u00e9o ph\u00ec, HbA1c c\u00f2n cao d\u00f9 \u0111\u00e3 d\u00f9ng metformin, ho\u1eb7c ng\u01b0\u1eddi c\u1ea7n tr\u00e1nh t\u0103ng c\u00e2n\/h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft do thu\u1ed1c kh\u00e1c.<\/p>\n

Ch\u1ec9 \u0111\u1ecbnh th\u1ef1c h\u00e0nh th\u01b0\u1eddng g\u1eb7p:<\/strong><\/h2>\n

\u2022 \u0110\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 ch\u01b0a \u0111\u1ea1t m\u1ee5c ti\u00eau v\u1edbi thay \u0111\u1ed5i l\u1ed1i s\u1ed1ng v\u00e0\/ho\u1eb7c metformin.<\/p>\n

\u2022 \u0110\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 c\u00f3 b\u00e9o ph\u00ec ho\u1eb7c c\u1ea7n gi\u1ea3m c\u00e2n \u0111\u1ec3 c\u1ea3i thi\u1ec7n chuy\u1ec3n h\u00f3a.<\/p>\n

\u2022 \u0110\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 \u0111ang d\u00f9ng insulin n\u1ec1n nh\u01b0ng c\u00f2n ki\u1ec3m so\u00e1t k\u00e9m, mu\u1ed1n gi\u1ea3m nhu c\u1ea7u insulin v\u00e0 h\u1ea1n ch\u1ebf t\u0103ng c\u00e2n.<\/p>\n

\u2022 Ng\u01b0\u1eddi b\u1ec7nh c\u1ea7n m\u1ed9t thu\u1ed1c c\u00f3 hi\u1ec7u l\u1ef1c r\u1ea5t cao nh\u01b0ng mu\u1ed1n tr\u00e1nh h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft ki\u1ec3u sulfonylurea\/insulin.<\/p>\n

Ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh ch\u00ednh theo nh\u00e3n FDA:<\/strong><\/h2>\n

\u2022 Ti\u1ec1n s\u1eed c\u00e1 nh\u00e2n ho\u1eb7c gia \u0111\u00ecnh ung th\u01b0 tuy\u1ebfn gi\u00e1p th\u1ec3 t\u1ee7y (MTC).<\/p>\n

\u2022 H\u1ed9i ch\u1ee9ng \u0111a u n\u1ed9i ti\u1ebft type 2 (MEN2).<\/p>\n

\u2022 Ti\u1ec1n s\u1eed qu\u00e1 m\u1eabn n\u1eb7ng v\u1edbi tirzepatide ho\u1eb7c b\u1ea5t k\u1ef3 t\u00e1 d\u01b0\u1ee3c n\u00e0o c\u1ee7a thu\u1ed1c.<\/p>\n

C\u00e1c t\u00ecnh hu\u1ed1ng c\u1ea7n th\u1eadn tr\u1ecdng h\u01a1n l\u00e0 ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh tuy\u1ec7t \u0111\u1ed1i:<\/strong><\/h2>\n

\u2022 Ti\u1ec1n s\u1eed vi\u00eam t\u1ee5y: EMA n\u00eau thu\u1ed1c ch\u01b0a \u0111\u01b0\u1ee3c nghi\u00ean c\u1ee9u \u0111\u1ea7y \u0111\u1ee7 \u1edf nh\u00f3m n\u00e0y v\u00e0 n\u00ean d\u00f9ng th\u1eadn tr\u1ecdng.<\/p>\n

\u2022 Li\u1ec7t d\u1ea1 d\u00e0y n\u1eb7ng\/gastroparesis n\u1eb7ng: FDA kh\u00f4ng khuy\u1ebfn c\u00e1o d\u00f9ng.<\/p>\n

\u2022 B\u1ec7nh v\u00f5ng m\u1ea1c \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng c\u00f3 nguy c\u01a1 ti\u1ebfn tri\u1ec3n: c\u1ea7n theo d\u00f5i s\u00e1t khi \u0111\u01b0\u1eddng huy\u1ebft c\u1ea3i thi\u1ec7n nhanh.<\/p>\n

\u2022 Ph\u1ee5 n\u1eef c\u00f3 thai ho\u1eb7c d\u1ef1 \u0111\u1ecbnh c\u00f3 thai: kh\u00f4ng n\u00ean d\u00f9ng th\u01b0\u1eddng quy.<\/p>\n

\u2022 \u0110ang d\u00f9ng thu\u1ed1c tr\u00e1nh thai \u0111\u01b0\u1eddng u\u1ed1ng ho\u1eb7c thu\u1ed1c u\u1ed1ng c\u00f3 kho\u1ea3ng \u0111i\u1ec1u tr\u1ecb h\u1eb9p: c\u1ea7n l\u01b0u \u00fd t\u01b0\u01a1ng t\u00e1c h\u1ea5p thu do ch\u1eadm r\u1ed7ng d\u1ea1 d\u00e0y.<\/p>\n

5. T\u00e1c d\u1ee5ng ph\u1ee5 v\u00e0 c\u1ea3nh b\u00e1o an to\u00e0n<\/strong><\/h1>\n

T\u00e1c d\u1ee5ng ph\u1ee5 th\u01b0\u1eddng g\u1eb7p nh\u1ea5t c\u1ee7a tirzepatide l\u00e0 tr\u00ean \u0111\u01b0\u1eddng ti\u00eau h\u00f3a. Theo nh\u00e3n FDA, c\u00e1c ph\u1ea3n \u1ee9ng b\u1ea5t l\u1ee3i g\u1eb7p t\u1eeb \u22655% b\u1ec7nh nh\u00e2n g\u1ed3m: bu\u1ed3n n\u00f4n, ti\u00eau ch\u1ea3y, gi\u1ea3m c\u1ea3m gi\u00e1c th\u00e8m \u0103n, n\u00f4n, t\u00e1o b\u00f3n, kh\u00f3 ti\u00eau v\u00e0 \u0111au b\u1ee5ng. Trong \u0111a s\u1ed1 tr\u01b0\u1eddng h\u1ee3p, tri\u1ec7u ch\u1ee9ng x\u1ea3y ra s\u1edbm trong giai \u0111o\u1ea1n kh\u1edfi tr\u1ecb ho\u1eb7c t\u0103ng li\u1ec1u, m\u1ee9c \u0111\u1ed9 nh\u1eb9 \u0111\u1ebfn trung b\u00ecnh v\u00e0 gi\u1ea3m d\u1ea7n theo th\u1eddi gian.<\/p>\n

C\u00e1c t\u00e1c d\u1ee5ng ph\u1ee5 th\u01b0\u1eddng g\u1eb7p:<\/strong><\/h2>\n

\u2022 Bu\u1ed3n n\u00f4n, n\u00f4n, ti\u00eau ch\u1ea3y, t\u00e1o b\u00f3n, \u0111\u1ea7y b\u1ee5ng, kh\u00f3 ti\u00eau, \u0111au b\u1ee5ng.<\/p>\n

\u2022 Gi\u1ea3m c\u1ea3m gi\u00e1c th\u00e8m \u0103n, s\u1ee5t c\u00e2n.<\/p>\n

\u2022 \u1ee2 h\u01a1i, tr\u00e0o ng\u01b0\u1ee3c, kh\u00f3 ch\u1ecbu ti\u00eau h\u00f3a.<\/p>\n

\u2022 Ph\u1ea3n \u1ee9ng t\u1ea1i ch\u1ed7 ti\u00eam (\u00edt g\u1eb7p h\u01a1n so v\u1edbi t\u00e1c d\u1ee5ng ph\u1ee5 ti\u00eau h\u00f3a).<\/p>\n

C\u00e1c c\u1ea3nh b\u00e1o quan tr\u1ecdng c\u1ea7n nh\u1edb:<\/strong><\/h2>\n

\u2022 Vi\u00eam t\u1ee5y c\u1ea5p: ng\u1eebng thu\u1ed1c n\u1ebfu nghi ng\u1edd; kh\u00f4ng d\u00f9ng l\u1ea1i n\u1ebfu x\u00e1c \u0111\u1ecbnh vi\u00eam t\u1ee5y.<\/p>\n

\u2022 H\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft: ch\u1ee7 y\u1ebfu x\u1ea3y ra khi ph\u1ed1i h\u1ee3p v\u1edbi insulin ho\u1eb7c sulfonylurea.<\/p>\n

\u2022 M\u1ea5t n\u01b0\u1edbc v\u00e0 suy th\u1eadn c\u1ea5p do n\u00f4n\/ti\u00eau ch\u1ea3y k\u00e9o d\u00e0i: \u0111\u1eb7c bi\u1ec7t \u1edf ng\u01b0\u1eddi cao tu\u1ed5i, b\u1ec7nh th\u1eadn, d\u00f9ng l\u1ee3i ti\u1ec3u.<\/p>\n

\u2022 B\u1ec7nh t\u00fai m\u1eadt c\u1ea5p (s\u1ecfi m\u1eadt, vi\u00eam t\u00fai m\u1eadt): ngh\u0129 \u0111\u1ebfn khi \u0111au h\u1ea1 s\u01b0\u1eddn ph\u1ea3i, s\u1ed1t, bu\u1ed3n n\u00f4n k\u00e9o d\u00e0i.<\/p>\n

\u2022 Nguy c\u01a1 li\u00ean quan tuy\u1ebfn gi\u00e1p theo c\u1ea3nh b\u00e1o h\u1ed9p \u0111en c\u1ee7a FDA: ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh \u1edf ng\u01b0\u1eddi c\u00f3 MTC\/MEN2.<\/p>\n

\u2022 Ch\u1eadm r\u1ed7ng d\u1ea1 d\u00e0y: c\u1ea7n l\u01b0u \u00fd khi l\u00e0m th\u1ee7 thu\u1eadt\/g\u00e2y m\u00ea s\u00e2u ho\u1eb7c khi d\u00f9ng thu\u1ed1c u\u1ed1ng c\u1ea7n h\u1ea5p thu \u1ed5n \u0111\u1ecbnh.<\/p>\n

\u2022 B\u1ec7nh v\u00f5ng m\u1ea1c \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng c\u00f3 th\u1ec3 x\u1ea5u \u0111i t\u1ea1m th\u1eddi n\u1ebfu \u0111\u01b0\u1eddng huy\u1ebft c\u1ea3i thi\u1ec7n qu\u00e1 nhanh.<\/p>\n

\n\n\n\n
\n

\u0110i\u1ec3m r\u1ea5t quan tr\u1ecdng cho b\u00e1c s\u0129 \u0111a khoa:\u00a0<\/strong>khi b\u1ec7nh nh\u00e2n than bu\u1ed3n n\u00f4n nhi\u1ec1u, n\u00f4n nhi\u1ec1u, ti\u00eau ch\u1ea3y k\u00e9o d\u00e0i, \u0103n u\u1ed1ng k\u00e9m ho\u1eb7c \u0111au b\u1ee5ng d\u1eef d\u1ed9i, kh\u00f4ng n\u00ean ch\u1ec9 \u201c\u0111\u1ed9ng vi\u00ean c\u1ed1 d\u00f9ng ti\u1ebfp\u201d. C\u1ea7n \u0111\u00e1nh gi\u00e1 m\u1ea5t n\u01b0\u1edbc, x\u00e9t \u0111\u1ebfn vi\u00eam t\u1ee5y\/b\u1ec7nh t\u00fai m\u1eadt v\u00e0 \u0111i\u1ec1u ch\u1ec9nh ph\u00e1c \u0111\u1ed3 k\u1ecbp th\u1eddi.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

6. Li\u1ec1u d\u00f9ng v\u00e0 c\u00e1ch d\u00f9ng<\/strong><\/h1>\n

Ph\u00e1c \u0111\u1ed3 li\u1ec1u chu\u1ea9n theo nh\u00e3n FDA:<\/strong><\/h2>\n

\u2022 Kh\u1edfi \u0111\u1ea7u: 2,5 mg ti\u00eam d\u01b0\u1edbi da 1 l\u1ea7n\/tu\u1ea7n.<\/p>\n

\u2022 Sau 4 tu\u1ea7n: t\u0103ng l\u00ean 5 mg\/tu\u1ea7n.<\/p>\n

\u2022 N\u1ebfu c\u1ea7n ki\u1ec3m so\u00e1t \u0111\u01b0\u1eddng huy\u1ebft th\u00eam: t\u0103ng t\u1eebng n\u1ea5c 2,5 mg sau \u00edt nh\u1ea5t 4 tu\u1ea7n \u1edf m\u1ed7i m\u1ee9c li\u1ec1u.<\/p>\n

\u2022 C\u00e1c m\u1ee9c li\u1ec1u duy tr\u00ec th\u01b0\u1eddng d\u00f9ng: 5 mg, 10 mg, 15 mg\/tu\u1ea7n.<\/p>\n

\u2022 Li\u1ec1u t\u1ed1i \u0111a \u1edf ng\u01b0\u1eddi l\u1edbn theo nh\u00e3n FDA\/EMA: 15 mg\/tu\u1ea7n.<\/p>\n

C\u00e1ch d\u00f9ng th\u1ef1c h\u00e0nh:<\/strong><\/h2>\n

\u2022 Ti\u00eam d\u01b0\u1edbi da \u1edf b\u1ee5ng, \u0111\u00f9i ho\u1eb7c m\u1eb7t sau c\u00e1nh tay.<\/p>\n

\u2022 Ti\u00eam c\u00f9ng m\u1ed9t ng\u00e0y c\u1ed1 \u0111\u1ecbnh m\u1ed7i tu\u1ea7n; c\u00f3 th\u1ec3 \u0111\u1ed5i ng\u00e0y n\u1ebfu kho\u1ea3ng c\u00e1ch gi\u1eefa hai li\u1ec1u \u00edt nh\u1ea5t 72 gi\u1edd.<\/p>\n

\u2022 N\u1ebfu qu\u00ean li\u1ec1u: d\u00f9ng c\u00e0ng s\u1edbm c\u00e0ng t\u1ed1t trong v\u00f2ng 4 ng\u00e0y (96 gi\u1edd); n\u1ebfu qu\u00e1 4 ng\u00e0y th\u00ec b\u1ecf qua li\u1ec1u qu\u00ean v\u00e0 ti\u00eam li\u1ec1u k\u1ebf ti\u1ebfp \u0111\u00fang l\u1ecbch.<\/p>\n

\u2022 Kh\u00f4ng t\u1ef1 t\u0103ng li\u1ec1u nhanh v\u00ec mu\u1ed1n gi\u1ea3m c\u00e2n nhanh h\u01a1n; t\u0103ng li\u1ec1u qu\u00e1 s\u1edbm l\u00e0m t\u0103ng \u0111\u00e1ng k\u1ec3 t\u00e1c d\u1ee5ng ph\u1ee5 ti\u00eau h\u00f3a.<\/p>\n

\u0110i\u1ec1u ch\u1ec9nh trong c\u00e1c t\u00ecnh hu\u1ed1ng ph\u1ed1i h\u1ee3p:<\/strong><\/h2>\n

\u2022 Khi d\u00f9ng c\u00f9ng sulfonylurea ho\u1eb7c insulin: c\u00e2n nh\u1eafc gi\u1ea3m li\u1ec1u thu\u1ed1c kia \u0111\u1ec3 h\u1ea1n ch\u1ebf h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft.<\/p>\n

\u2022 Thu\u1ed1c u\u1ed1ng c\u00f3 kho\u1ea3ng \u0111i\u1ec1u tr\u1ecb h\u1eb9p (v\u00ed d\u1ee5 warfarin, digoxin theo EMA; warfarin theo FDA): theo d\u00f5i k\u1ef9 h\u01a1n khi kh\u1edfi tr\u1ecb v\u00e0 m\u1ed7i l\u1ea7n t\u0103ng li\u1ec1u.<\/p>\n

\u2022 Thu\u1ed1c tr\u00e1nh thai \u0111\u01b0\u1eddng u\u1ed1ng: FDA khuy\u00ean \u0111\u1ed5i sang bi\u1ec7n ph\u00e1p tr\u00e1nh thai kh\u00f4ng \u0111\u01b0\u1eddng u\u1ed1ng ho\u1eb7c b\u1ed5 sung bi\u1ec7n ph\u00e1p h\u00e0ng r\u00e0o trong 4 tu\u1ea7n sau kh\u1edfi tr\u1ecb v\u00e0 4 tu\u1ea7n sau m\u1ed7i l\u1ea7n t\u0103ng li\u1ec1u.<\/p>\n

G\u1ee3i \u00fd t\u0103ng li\u1ec1u \u201c\u00eam\u201d \u0111\u1ec3 t\u0103ng kh\u1ea3 n\u0103ng dung n\u1ea1p<\/strong><\/h2>\n
\n\n\n\n\n\n\n
\n

Giai \u0111o\u1ea1n<\/strong><\/p>\n<\/td>\n

\n

Li\u1ec1u th\u01b0\u1eddng d\u00f9ng<\/strong><\/p>\n<\/td>\n

\n

M\u1ee5c ti\u00eau<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Tu\u1ea7n 1\u20134<\/p>\n<\/td>\n

\n

2,5 mg\/tu\u1ea7n<\/p>\n<\/td>\n

\n

L\u00e0m quen thu\u1ed1c, kh\u00f4ng xem l\u00e0 li\u1ec1u \u0111i\u1ec1u tr\u1ecb ch\u00ednh \u0111\u1ec3 ki\u1ec3m so\u00e1t \u0111\u01b0\u1eddng huy\u1ebft<\/p>\n<\/td>\n<\/tr>\n

\n

Tu\u1ea7n 5 tr\u1edf \u0111i<\/p>\n<\/td>\n

\n

5 mg\/tu\u1ea7n<\/p>\n<\/td>\n

\n

B\u1eaft \u0111\u1ea7u li\u1ec1u duy tr\u00ec c\u01a1 b\u1ea3n \u1edf nhi\u1ec1u b\u1ec7nh nh\u00e2n<\/p>\n<\/td>\n<\/tr>\n

\n

M\u1ed7i \u22654 tu\u1ea7n ti\u1ebfp theo n\u1ebfu c\u1ea7n<\/p>\n<\/td>\n

\n

7,5 \u2192 10 \u2192 12,5 \u2192 15 mg\/tu\u1ea7n<\/p>\n<\/td>\n

\n

T\u0103ng hi\u1ec7u l\u1ef1c khi HbA1c\/c\u00e2n n\u1eb7ng ch\u01b0a \u0111\u1ea1t m\u1ee5c ti\u00eau v\u00e0 b\u1ec7nh nh\u00e2n dung n\u1ea1p t\u1ed1t<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

7. T\u00ednh h\u1ee3p ph\u00e1p c\u1ee7a Tirzepatide \u1edf Vi\u1ec7t Nam v\u00e0 th\u1ebf gi\u1edbi<\/strong><\/h1>\n

Tr\u00ean th\u1ebf gi\u1edbi, tirzepatide \u0111\u00e3 c\u00f3 v\u1ecb tr\u00ed ph\u00e1p l\u00fd r\u00f5 r\u00e0ng t\u1ea1i nhi\u1ec1u c\u01a1 quan qu\u1ea3n l\u00fd l\u1edbn. FDA ph\u00ea duy\u1ec7t Mounjaro cho \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 t\u1eeb th\u00e1ng 5\/2022. FDA ti\u1ebfp t\u1ee5c ph\u00ea duy\u1ec7t Zepbound (c\u00f9ng ho\u1ea1t ch\u1ea5t tirzepatide) cho qu\u1ea3n l\u00fd c\u00e2n n\u1eb7ng m\u1ea1n t\u00ednh \u1edf ng\u01b0\u1eddi l\u1edbn \u0111\u1ee7 \u0111i\u1ec1u ki\u1ec7n v\u00e0o th\u00e1ng 11\/2023. EMA x\u00e1c nh\u1eadn Mounjaro \u0111\u01b0\u1ee3c d\u00f9ng cho \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 v\u00e0 c\u1ea3 qu\u1ea3n l\u00fd c\u00e2n n\u1eb7ng t\u1ea1i Li\u00ean minh ch\u00e2u \u00c2u; MHRA c\u1ee7a Anh c\u0169ng \u0111\u00e3 cho ph\u00e9p s\u1eed d\u1ee5ng trong c\u00e1c ch\u1ec9 \u0111\u1ecbnh t\u01b0\u01a1ng \u1ee9ng.<\/p>\n

\u1ede b\u00ecnh di\u1ec7n ch\u00ednh s\u00e1ch qu\u1ed1c t\u1ebf, WHO \u0111\u00e3 c\u1eadp nh\u1eadt Danh m\u1ee5c Thu\u1ed1c thi\u1ebft y\u1ebfu n\u0103m 2025 \u0111\u1ec3 bao g\u1ed3m nh\u00f3m GLP-1 receptor agonists v\u00e0 thu\u1ed1c \u0111\u1ed3ng v\u1eadn k\u00e9p GIP\/GLP-1 l\u00e0 tirzepatide cho c\u00e1c nh\u00f3m b\u1ec7nh nh\u00e2n \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 c\u00f3 l\u1ee3i \u00edch r\u00f5 nh\u1ea5t (\u0111\u1eb7c bi\u1ec7t khi k\u00e8m b\u1ec7nh tim m\u1ea1ch ho\u1eb7c th\u1eadn v\u00e0 b\u00e9o ph\u00ec). WHO \u0111\u1ed3ng th\u1eddi c\u1ea3nh b\u00e1o v\u1ea5n \u0111\u1ec1 ti\u1ebfp c\u1eadn, gi\u00e1 th\u00e0nh v\u00e0 nguy c\u01a1 thu\u1ed1c gi\u1ea3\/substandard \u1edf nh\u00f3m thu\u1ed1c GLP-1.<\/p>\n

T\u1ea1i Vi\u1ec7t Nam:<\/strong><\/h2>\n

Kh\u00f4ng t\u00ecm th\u1ea5y m\u1ed9t trang c\u00f4ng khai r\u00f5 r\u00e0ng t\u1eeb B\u1ed9 Y t\u1ebf\/C\u1ee5c Qu\u1ea3n l\u00fd D\u01b0\u1ee3c x\u00e1c nh\u1eadn t\u00ecnh tr\u1ea1ng \u0111\u0103ng k\u00fd l\u01b0u h\u00e0nh ch\u00ednh th\u1ee9c c\u1ee7a tirzepatide t\u1ea1i Vi\u1ec7t Nam t\u00ednh \u0111\u1ebfn ng\u00e0y 06\/03\/2026 trong ph\u1ea1m vi ngu\u1ed3n c\u00f4ng khai truy xu\u1ea5t \u0111\u01b0\u1ee3c.<\/p>\n

8. C\u00e1c nghi\u00ean c\u1ee9u l\u1edbn v\u1ec1 tirzepatide trong \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng<\/strong><\/h1>\n

D\u1eef li\u1ec7u n\u1ec1n t\u1ea3ng c\u1ee7a tirzepatide ch\u1ee7 y\u1ebfu \u0111\u1ebfn t\u1eeb ch\u01b0\u01a1ng tr\u00ecnh SURPASS trong \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2. \u0110\u00e2y l\u00e0 chu\u1ed7i th\u1eed nghi\u1ec7m pha 3 so s\u00e1nh v\u1edbi gi\u1ea3 d\u01b0\u1ee3c ho\u1eb7c thu\u1ed1c \u0111ang d\u00f9ng ph\u1ed5 bi\u1ebfn trong nhi\u1ec1u b\u1ed1i c\u1ea3nh l\u00e2m s\u00e0ng kh\u00e1c nhau.<\/p>\n

\n\n\n\n\n\n\n\n\n\n
\n

Nghi\u00ean c\u1ee9u<\/strong><\/p>\n<\/td>\n

\n

\u0110\u1ed1i t\u01b0\u1ee3ng\/ch\u1ecdn so s\u00e1nh<\/strong><\/p>\n<\/td>\n

\n

K\u1ebft qu\u1ea3 ch\u00ednh<\/strong><\/p>\n<\/td>\n

\n

\u00dd ngh\u0129a th\u1ef1c h\u00e0nh<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

SURPASS-1<\/p>\n<\/td>\n

\n

\u0110\u01a1n tr\u1ecb \u1edf t\u00edp 2, so v\u1edbi gi\u1ea3 d\u01b0\u1ee3c<\/p>\n<\/td>\n

\n

Ch\u1ee9ng minh tirzepatide h\u1ea1 HbA1c m\u1ea1nh v\u00e0 gi\u1ea3m c\u00e2n r\u00f5 ngay c\u1ea3 khi d\u00f9ng \u0111\u01a1n tr\u1ecb<\/p>\n<\/td>\n

\n

Ph\u00f9 h\u1ee3p \u0111\u1ec3 hi\u1ec3u hi\u1ec7u l\u1ef1c \u201cth\u1ef1c\u201d c\u1ee7a thu\u1ed1c khi ch\u01b0a c\u00f3 n\u1ec1n \u0111i\u1ec1u tr\u1ecb ph\u1ee9c t\u1ea1p<\/p>\n<\/td>\n<\/tr>\n

\n

SURPASS-2<\/p>\n<\/td>\n

\n

Th\u00eam v\u00e0o metformin, so v\u1edbi semaglutide 1 mg\/tu\u1ea7n<\/p>\n<\/td>\n

\n

Tirzepatide kh\u00f4ng k\u00e9m h\u01a1n v\u00e0 v\u01b0\u1ee3t tr\u1ed9i semaglutide 1 mg v\u1ec1 gi\u1ea3m HbA1c; \u0111\u1ed3ng th\u1eddi gi\u1ea3m c\u00e2n nhi\u1ec1u h\u01a1n<\/p>\n<\/td>\n

\n

D\u1eef li\u1ec7u \u0111\u1ea7u \u0111\u1ed1i \u0111\u1ea7u r\u1ea5t quan tr\u1ecdng khi so s\u00e1nh v\u1edbi GLP-1 RA kinh \u0111i\u1ec3n<\/p>\n<\/td>\n<\/tr>\n

\n

SURPASS-3<\/p>\n<\/td>\n

\n

So v\u1edbi insulin degludec \u1edf b\u1ec7nh nh\u00e2n \u0111ang d\u00f9ng metformin \u00b1 SGLT2i<\/p>\n<\/td>\n

\n

Tirzepatide v\u01b0\u1ee3t tr\u1ed9i insulin degludec v\u1ec1 HbA1c v\u00e0 gi\u1ea3m c\u00e2n, v\u1edbi nguy c\u01a1 h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft th\u1ea5p h\u01a1n<\/p>\n<\/td>\n

\n

R\u1ea5t h\u1eefu \u00edch khi quy\u1ebft \u0111\u1ecbnh \u201cth\u00eam tirzepatide hay l\u00ean insulin n\u1ec1n\u201d<\/p>\n<\/td>\n<\/tr>\n

\n

SURPASS-4<\/p>\n<\/td>\n

\n

So v\u1edbi insulin glargine \u1edf b\u1ec7nh nh\u00e2n t\u00edp 2 c\u00f3 nguy c\u01a1 tim m\u1ea1ch cao<\/p>\n<\/td>\n

\n

Ti\u1ebfp t\u1ee5c cho th\u1ea5y h\u1ea1 HbA1c, gi\u1ea3m c\u00e2n t\u1ed1t h\u01a1n; d\u1eef li\u1ec7u k\u00e9o d\u00e0i t\u1edbi 104 tu\u1ea7n c\u1ee7ng c\u1ed1 t\u00ednh b\u1ec1n v\u1eefng<\/p>\n<\/td>\n

\n

H\u1ed7 tr\u1ee3 d\u00f9ng \u1edf nh\u00f3m nguy c\u01a1 tim m\u1ea1ch cao c\u1ea7n tr\u00e1nh t\u0103ng c\u00e2n\/h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft<\/p>\n<\/td>\n<\/tr>\n

\n

SURPASS-5<\/p>\n<\/td>\n

\n

B\u1ed5 sung tr\u00ean n\u1ec1n insulin glargine \u00b1 metformin, so v\u1edbi gi\u1ea3 d\u01b0\u1ee3c<\/p>\n<\/td>\n

\n

C\u1ea3i thi\u1ec7n HbA1c v\u00e0 c\u00e2n n\u1eb7ng r\u00f5, \u0111\u1ed3ng th\u1eddi gi\u1ea3m nhu c\u1ea7u t\u0103ng li\u1ec1u insulin n\u1ec1n<\/p>\n<\/td>\n

\n

C\u00f3 gi\u00e1 tr\u1ecb cao trong th\u1ef1c h\u00e0nh ph\u1ed1i h\u1ee3p v\u1edbi insulin n\u1ec1n<\/p>\n<\/td>\n<\/tr>\n

\n

SURPASS-CVOT<\/p>\n<\/td>\n

\n

So v\u1edbi dulaglutide \u1edf b\u1ec7nh nh\u00e2n t\u00edp 2 c\u00f3 ASCVD<\/p>\n<\/td>\n

\n

K\u1ebft qu\u1ea3 cho th\u1ea5y tirzepatide kh\u00f4ng k\u00e9m h\u01a1n dulaglutide v\u1ec1 bi\u1ebfn c\u1ed1 tim m\u1ea1ch ch\u00ednh; \u0111\u1ed3ng th\u1eddi cho c\u1ea3i thi\u1ec7n chuy\u1ec3n h\u00f3a v\u00e0 c\u00e2n n\u1eb7ng t\u1ed1t h\u01a1n<\/p>\n<\/td>\n

\n

Quan tr\u1ecdng v\u00ec cho th\u1ea5y thu\u1ed1c an to\u00e0n tim m\u1ea1ch theo chu\u1ea9n CVOT, d\u00f9 hi\u1ec7n di\u1ec5n gi\u1ea3i ch\u1ec9 \u0111\u1ecbnh gi\u1ea3m nguy c\u01a1 tim m\u1ea1ch c\u00f2n ph\u1ee5 thu\u1ed9c nh\u00e3n t\u1eebng qu\u1ed1c gia<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

T\u1ed5ng h\u1ee3p t\u1eeb c\u00e1c SURPASS \u0111\u00e3 ho\u00e0n t\u1ea5t:<\/strong><\/h2>\n

\u2022 Gi\u1ea3m HbA1c kho\u1ea3ng 1,87% \u0111\u1ebfn 2,59% t\u00f9y th\u1eed nghi\u1ec7m v\u00e0 li\u1ec1u.<\/p>\n

\u2022 Gi\u1ea3m c\u00e2n kho\u1ea3ng 6,2 kg \u0111\u1ebfn 12,9 kg t\u1ea1i c\u00e1c m\u1ed1c ch\u00ednh 40\u201352 tu\u1ea7n.<\/p>\n

\u2022 T\u1ef7 l\u1ec7 \u0111\u1ea1t HbA1c <7% dao \u0111\u1ed9ng 81\u201397%; \u0111\u1ea1t \u22646,5% kho\u1ea3ng 66\u201395%.<\/p>\n

\u2022 T\u00e1c d\u1ee5ng ph\u1ee5 ch\u1ee7 y\u1ebfu l\u00e0 ti\u00eau h\u00f3a; nh\u00ecn chung h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft th\u1ea5p n\u1ebfu kh\u00f4ng ph\u1ed1i h\u1ee3p insulin\/SU.<\/p>\n

\u2022 SURPASS-CVOT (NEJM 2025) cho th\u1ea5y tirzepatide kh\u00f4ng k\u00e9m h\u01a1n dulaglutide tr\u00ean bi\u1ebfn c\u1ed1 tim m\u1ea1ch ch\u00ednh \u1edf ng\u01b0\u1eddi b\u1ec7nh t\u00edp 2 c\u00f3 ASCVD.<\/p>\n

9. K\u1ebft lu\u1eadn th\u1ef1c h\u00e0nh<\/strong><\/h1>\n

Tirzepatide l\u00e0 m\u1ed9t trong nh\u1eefng thu\u1ed1c h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft c\u00f3 hi\u1ec7u qu\u1ea3 m\u1ea1nh nh\u1ea5t hi\u1ec7n nay \u0111\u1ed1i v\u1edbi ng\u01b0\u1eddi b\u1ec7nh \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2, \u0111\u1eb7c bi\u1ec7t khi k\u00e8m th\u1eeba c\u00e2n ho\u1eb7c b\u00e9o ph\u00ec. Thu\u1ed1c ph\u00f9 h\u1ee3p v\u1edbi xu h\u01b0\u1edbng \u0111i\u1ec1u tr\u1ecb hi\u1ec7n \u0111\u1ea1i: ki\u1ec3m so\u00e1t \u0111\u01b0\u1eddng huy\u1ebft \u0111i c\u00f9ng ki\u1ec3m so\u00e1t c\u00e2n n\u1eb7ng, gi\u1ea3m g\u00e1nh n\u1eb7ng h\u1ea1 \u0111\u01b0\u1eddng huy\u1ebft v\u00e0 h\u01b0\u1edbng t\u1edbi l\u1ee3i \u00edch tim-th\u1eadn-chuy\u1ec3n h\u00f3a to\u00e0n di\u1ec7n.<\/p>\n

Tuy nhi\u00ean, \u0111\u00e2y kh\u00f4ng ph\u1ea3i l\u00e0 \u201cthu\u1ed1c th\u1ea7n k\u1ef3\u201d. Hi\u1ec7u qu\u1ea3 t\u1ed1t nh\u1ea5t \u0111\u1ea1t \u0111\u01b0\u1ee3c khi ch\u1ecdn \u0111\u00fang b\u1ec7nh nh\u00e2n, t\u0103ng li\u1ec1u ch\u1eadm, gi\u1ea3i th\u00edch k\u1ef9 t\u00e1c d\u1ee5ng ph\u1ee5, ki\u1ec3m tra t\u01b0\u01a1ng t\u00e1c v\u00e0 x\u00e1c minh t\u00ecnh tr\u1ea1ng ph\u00e1p l\u00fd\/ngu\u1ed3n g\u1ed1c thu\u1ed1c.<\/p>\n

T\u00e0i li\u1ec7u tham kh\u1ea3o<\/strong><\/h1>\n

1. American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S183-S206.<\/p>\n

2. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786.<\/p>\n

3. World Health Organization. WHO updates list of essential medicines to include key cancer, diabetes treatments. Geneva: WHO; 2025.<\/p>\n

4. World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. Geneva: WHO; 2025.<\/p>\n

5. U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, for subcutaneous use: prescribing information. Silver Spring, MD: FDA; revised 2025.<\/p>\n

6. European Medicines Agency. Mounjaro (tirzepatide): medicine overview and product information. Amsterdam: EMA; updated 2026.<\/p>\n

7. U.S. Food and Drug Administration. FDA approves new medication for chronic weight management. Silver Spring, MD: FDA; 2023.<\/p>\n

8. Medicines and Healthcare products Regulatory Agency. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss. London: MHRA; 2023.<\/p>\n

9. Kushner P, Frias JP, Bailey TS, Rosenstock J, Thomsen M, Karanikas CA, et al. Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers. Clin Diabetes. 2023;41(2):190-204.<\/p>\n

10. Frias JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503-515.<\/p>\n

11. Ludvik B, Giorgino F, Jodar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K, et al. Once-weekly tirzepatide versus insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021;398:583-598.<\/p>\n

12. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545.<\/p>\n

13. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398:1811-1824.<\/p>\n

14. Nicholls SJ, Bhatt DL, Cannon CP, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025<\/p>\n","protected":false},"excerpt":{"rendered":"

Th\u00f4ng \u0111i\u1ec7p ch\u00ednh:\u00a0Tirzepatide l\u00e0 thu\u1ed1c \u0111\u1ed3ng v\u1eadn k\u00e9p GIP\/GLP-1, ti\u00eam d\u01b0\u1edbi da 1 l\u1ea7n\/tu\u1ea7n, c\u00f3 hi\u1ec7u qu\u1ea3 h\u1ea1 HbA1c v\u00e0 gi\u1ea3m c\u00e2n r\u1ea5t m\u1ea1nh. Thu\u1ed1c \u0111\u1eb7c bi\u1ec7t h\u1eefu \u00edch \u1edf ng\u01b0\u1eddi \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng t\u00edp 2 c\u00f3 th\u1eeba c\u00e2n\/b\u00e9o ph\u00ec, nh\u01b0ng c\u1ea7n ch\u1ecdn \u0111\u00fang b\u1ec7nh nh\u00e2n, t\u0103ng li\u1ec1u t\u1eeb t\u1eeb v\u00e0 theo d\u00f5i t\u00e1c d\u1ee5ng […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[18],"tags":[],"class_list":["post-483","post","type-post","status-publish","format-standard","hentry","category-tieu-duong"],"blocksy_meta":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/posts\/483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/comments?post=483"}],"version-history":[{"count":2,"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/posts\/483\/revisions"}],"predecessor-version":[{"id":485,"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/posts\/483\/revisions\/485"}],"wp:attachment":[{"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/media?parent=483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/categories?post=483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cctravelesthetic.com\/vi\/wp-json\/wp\/v2\/tags?post=483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}